Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate
1. Precision BioSciences reveals initial results from PBGENE-HBV trial. 2. ELIMINATE-B trial investigates multiple ascending doses for chronic Hepatitis B. 3. PBGENE-HBV shows safety and antiviral activity in cohort 1 participants. 4. Participants experienced no serious treatment-related adverse events. 5. HC Wainwright maintains a $60 price target for Precision BioSciences.